Summary

Report Overview
Europe Diabetes Devices Market reached US$ 9.2 billion in 2023 and is expected to reach US$ 12.4 billion by 2031, growing at a CAGR of 8.7% during the forecast period 2024-2031.
Diabetes is a group of metabolic disorders characterized by a chronically high blood sugar level. Common symptoms include frequent urination, increased thirst, and increased hunger. Diabetes, if untreated, may cause an array of health problems.
Acute consequences include diabetic ketoacidosis, hyperosmolar hyperglycemia, and death. Long-term risks include cardiovascular illness, stroke, chronic kidney disease, foot ulcers, nerve damage, eye damage, and cognitive impairment. Diabetes devices are used to monitor and manage the disease symptoms and are useful for estimating the onset of the adverse effects of the disease.
Market Dynamics: Drivers & Restraints
Rising incidence of diabetes
Diabetes is one of the most common chronic conditions in the WHO European Region, and Europe has the highest burden of type 1 diabetes in the world. According to the WHO report in 2024, it is estimated that 1 in 10 people living in the Region will have diabetes by 2045.
An estimated 74 million adults (11.9% of men and 10.9% of women) and around 300,000 children and adolescents are living with diabetes in the WHO European Region, which has the highest burden of type 1 diabetes in the world.
The increasing diabetic population in the region increases the adoption of diabetic management and monitoring devices which shows a positive impact on the expansion in the market growth.
High costs associated with diabetes devices
Diabetic devices such as continuous glucose monitors (CGMs) and insulin pumps, are costly and cannot be afforded by many individuals. For patients, particularly those without insurance or in areas with limited resources for healthcare, high expenses can be challenging. Thus, the high costs of these devices could hamper the market growth.
Market Segment Analysis
The Europe diabetes devices market is segmented based on device type, and distribution channel.
The blood glucose monitoring (BGM) devices segment is expected to dominate the market share
Blood glucose monitoring (BGM) devices hold a major portion of the market share and are expected to continue throughout the forecast period. This is due to the increasing technological advancements in the devices and the increasing number of launches of the devices. The increasing patient pool of diabetes in the region also plays a dominant role in holding the segment in a significant position in the market share.
Blood glucose monitoring devices help in monitoring the levels of glucose present in the blood and allow them to manage their health conditions and plan the treatment. Additionally, the advanced features of the blood glucose monitors allow them to adopt these BGM expanding the segment growth.
Medical device manufacturing companies are introducing advanced devices that are accurate and efficient. For instance, in July 2024, Roche secured approval in Europe for its artificial intelligence-powered continuous glucose monitoring system with a green light for adults with Type 1 or Type 2 diabetes who rely on real-time readings to adjust their insulin doses.
Market Segmentation
By Device Type
Blood Glucose Monitoring (BGM) Devices
Self-Monitoring Devices
Blood Glucose Meters
Testing Strips
Lancets
Continuous Glucose Monitoring Devices
Sensors
Durables
Others
Insulin Delivery Devices
Insulin Pumps
Insulin Pens
Insulin Syringes
Jet Injectors
Others
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Diabetes Clinics/Centers
Online Pharmacies
Others
Market Competitive Landscape
The major players in the market include Novo Nordisk A/S, Abbott Laboratories, Nipro Medical Europe, Afon Technology Ltd, GlucoRx Limited, Ascensia Diabetes Care UK Limited, SIBIONICS, Roche Diabetes Care, Kinetik Medical Devices Limited AND Dexcom, Inc. among others.
Why Purchase the Report?
To visualize the Europe diabetes devices market segmentation based on device type, and distribution channel, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of diabetes devices market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.
The Europe diabetes devices market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Device Type
3.2. Snippet by Distribution Channel
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising incidence of diabetes
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High costs associated with diabetes devices
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Device Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
6.1.2. Market Attractiveness Index, By Device Type
6.2. Blood Glucose Monitoring (BGM) Devices*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Self-Monitoring Devices
6.2.3.1. Blood Glucose Meters
6.2.3.2. Testing Strips
6.2.3.3. Lancets
6.2.4. Continuous Glucose Monitoring Devices
6.2.4.1. Sensors
6.2.4.2. Durables
6.2.4.3. Others
6.3. Insulin Delivery Devices
6.3.1. Insulin Pumps
6.3.2. Insulin Pens
6.3.3. Insulin Syringes
6.3.4. Jet Injectors
6.3.5. Others
6.4. Others
7. By Distribution Channel
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
7.1.2. Market Attractiveness Index, By Distribution Channel
7.2. Hospital Pharmacies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Retail Pharmacies
7.4. Diabetes Clinics/Centers
7.5. Online Pharmacies
7.6. Others
8. Competitive Landscape
8.1. Competitive Scenario
8.2. Market Positioning/Share Analysis
8.3. Mergers and Acquisitions Analysis
9. Company Profiles
9.1. Novo Nordisk A/S*
9.1.1. Company Overview
9.1.2. Product Portfolio and Description
9.1.3. Financial Overview
9.1.4. Key Developments
9.2. Abbott Laboratories
9.3. Nipro Medical Europe
9.4. Afon Technology Ltd
9.5. GlucoRx Limited
9.6. Ascensia Diabetes Care UK Limited
9.7. SIBIONICS
9.8. Roche Diabetes Care
9.9. Kinetik Medical Devices Limited
9.10. Dexcom, Inc. (*LIST NOT EXHAUSTIVE)
10. Appendix
10.1. About Us and Services
10.2. Contact Us